PubMed

Emerging evidence of a link between the polycystins and the mTOR pathways.

Boletta A.

Pathogenetics. 2009 Oct 28;2(1):6.PMID: 19863783 [PubMed - in process]Free PMC ArticleFree textRelated citations

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.

Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM.

PLoS Biol. 2009 Feb 10;7(2):e38.PMID: 19209957 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Monitoring mammalian target of rapamycin (mTOR) activity.

Ikenoue T, Hong S, Inoki K.

Methods Enzymol. 2009;452:165-80.PMID: 19200882 [PubMed - indexed for MEDLINE]Related citations

Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR.

Dere R, Wilson PD, Sandford RN, Walker CL.

PLoS One. 2010 Feb 16;5(2):e9239.PMID: 20169078 [PubMed - in process]Free PMC ArticleFree textRelated citations

Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.

Huang J, Wu S, Wu CL, Manning BD.

Cancer Res. 2009 Aug 1;69(15):6107-14. Epub 2009 Jul 14.PMID: 19602587 [PubMed - indexed for MEDLINE]Related citations

Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.

Gulati N, Karsy M, Albert L, Murali R, Jhanwar-Uniyal M.

Int J Oncol. 2009 Oct;35(4):731-40.PMID: 19724909 [PubMed - indexed for MEDLINE]Related citations

The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway.

Hartman TR, Liu D, Zilfou JT, Robb V, Morrison T, Watnick T, Henske EP.

Hum Mol Genet. 2009 Jan 1;18(1):151-63. Epub 2008 Oct 9.PMID: 18845692 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?

Corradetti MN, Guan KL.

Oncogene. 2006 Oct 16;25(48):6347-60. Review.PMID: 17041621 [PubMed - indexed for MEDLINE]Related citations

Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle.

Rosner M, Fuchs C, Siegel N, Valli A, Hengstschläger M.

Hum Mol Genet. 2009 Sep 1;18(17):3298-310. Epub 2009 Jun 8.PMID: 19505958 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.

Rosner M, Hengstschläger M.

Hum Mol Genet. 2008 Oct 1;17(19):2934-48. Epub 2008 Jul 8.PMID: 18614546 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.

Wysocki PJ.

Expert Rev Mol Diagn. 2009 Apr;9(3):231-41. Review.PMID: 19379082 [PubMed - indexed for MEDLINE]Related citations

Do polycystins function as cation channels?

Ikeda M, Guggino WB.

Curr Opin Nephrol Hypertens. 2002 Sep;11(5):539-45. Review.PMID: 12187319 [PubMed - indexed for MEDLINE]Related citations

Isolation of hyperactive mutants of mammalian target of rapamycin.

Ohne Y, Takahara T, Hatakeyama R, Matsuzaki T, Noda M, Mizushima N, Maeda T.

J Biol Chem. 2008 Nov 14;283(46):31861-70. Epub 2008 Sep 23.PMID: 18812319 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?

Weimbs T.

Cell Cycle. 2006 Nov 1;5(21):2425-9. Epub 2006 Sep 13. Review.PMID: 17102641 [PubMed - indexed for MEDLINE]Related citations

Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.

Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA.

Mol Cell Biol. 2009 Mar;29(6):1411-20. Epub 2008 Dec 29.PMID: 19114562 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

mTOR in growth and protection of hypertrophying myocardium.

Balasubramanian S, Johnston RK, Moschella PC, Mani SK, Tuxworth WJ Jr, Kuppuswamy D.

Cardiovasc Hematol Agents Med Chem. 2009 Jan;7(1):52-63. Review.PMID: 19149544 [PubMed - indexed for MEDLINE]Related citations

Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.

Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, Wallace DP, Weimbs T, Wüthrich RP.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1312-29. Epub 2010 May 24.PMID: 20498248 [PubMed - in process]Related citations

Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.

Fu L, Kim YA, Wang X, Wu X, Yue P, Lonial S, Khuri FR, Sun SY.

Cancer Res. 2009 Dec 1;69(23):8967-76. Epub 2009 Nov 17.PMID: 19920197 [PubMed - indexed for MEDLINE]Related citations

Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly.

Kaizuka T, Hara T, Oshiro N, Kikkawa U, Yonezawa K, Takehana K, Iemura S, Natsume T, Mizushima N.

J Biol Chem. 2010 Jun 25;285(26):20109-16. Epub 2010 Apr 28.PMID: 20427287 [PubMed - in process]Related citations

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A.

Cancer Res. 2009 Aug 1;69(15):6232-40. Epub 2009 Jul 7.PMID: 19584280 [PubMed - indexed for MEDLINE]Related citations